GlassScriptPhysician profile
Gary R Carpenter
NPI 1649533738
$3,785.96
in general payments reported to CMS, 2019-2025
31 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $306 · 2021: $110 · 2022: $82.98 · 2023: $336 · 2024: $1,013 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,175.47 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $668.65 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $394.07 | 2019-2025 | |
| Astellas Pharma US INC | $373.90 | 2023-2025 | Veozah |
| Novo Nordisk INC | $335.33 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $315.54 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $314.89 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $197.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.86 | 2022-2025 | |
| Exact Sciences Corporation | $123.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $92.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.80 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $75.60 | 2019 | |
| Pfizer INC. | $73.58 | 2024-2025 | |
| Insulet Corporation | $59.22 | 2024 | Omnipod |
| Janssen Biotech, INC. | $58.55 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.99 | 2024-2025 | Repatha, Otezla, Repatha |
| Shield Therapeutics INC | $46.05 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $45.27 | 2022-2023 | Amvuttra |
| Medtronic, INC. | $44.79 | 2025 | Minimed 780g |
| Mylan Pharmaceuticals INC. | $44.49 | 2019 | |
| Idorsia Pharmaceuticals US INC | $42.78 | 2023 | Quviviq |
| Atricure, INC. | $25.55 | 2020 | |
| Glaxosmithkline, LLC. | $24.93 | 2023 | Shingrix, Arexvy |
| Tactile Systems Technology INC | $24.35 | 2023 | Flexitouch Plus, Entre Plus |
| Amarin Pharma, INC. | $23.98 | 2020 | |
| Ardelyx, INC. | $23.33 | 2024 | Ibsrela |
| Allergan, INC. | $20.69 | 2020 | |
| Abbott Laboratories | $19.61 | 2020 | |
| Sanofi Pasteur INC. | $19.06 | 2019 | |
| Mylan Institutional INC. | $17.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.